News & Views
Investment to Support Technology Roll-Out
Jan 31 2018
Biomanufacturing company Univercells SA, (Gosselies, Belgium) has announced the successful closing of a €3 million ($3.56M) increase in a Series-A equity financing round, led by private investors from Europe and the US.
The capital injection will help enable the commercial introduction of the company’s viral micro-facility, with a first technology transfer anticipated for Q4 2018 within the framework of the Bill & Melinda Gates Foundation-supported program; it will also benefit the company’s recombinant platform development, both of which are aimed at providing a sufficient supply of high-quality biologics at an affordable price.
“We are very proud of this funding round and thankful for this wealth of support,” commented Hugues Bultot, co-founder and CEO of Univercells. “This successful capital increase is a real recognition of the work achieved so far, the innovative technology being developed and the clear expectations and roadmap set. It is highly encouraging to have seasoned industry experts demonstrate such tremendous confidence in Univercells, its ability to transform the industry with their willingness to contribute to our mission.”
Digital Edition
Lab Asia 31.2 April 2024
April 2024
In This Edition Chromatography Articles - Approaches to troubleshooting an SPE method for the analysis of oligonucleotides (pt i) - High-precision liquid flow processes demand full fluidic c...
View all digital editions
Events
Apr 22 2024 Marrakech, Morroco
Making Pharmaceuticals Exhibition & Conference
Apr 23 2024 Coventry, UK
Apr 23 2024 Kintex, South Korea
Apr 23 2024 Seoul, South Korea
Apr 24 2024 Jakarta, Indonesia